Autolus is growing revenue 118% YoY from a small base but burns cash at -171% of revenue, trades in a downtrend near $1.54, and has no usable analyst target after the raw figure was rejected as implausible.
Thesis pillars
- Cash Burn Funding Risk→Stable
- Rapid Revenue Growth→Stable
- Downtrend Pullback↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Mar 27, 2026
Autolus Therapeutics plc (AUTL) Stock Analysis
Oversold Bounce setup · Inst Constrain edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $1.38, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $8.75 vs price $1.38 — ratio 6.3×). Rejected, falling back to technical TP.; Market cap $367M below $400M minimum.
Autolus Therapeutics markets AUCATZYL (obe-cel), a CD19-targeted CAR T cell therapy for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia, approved by the FDA in November 2024 and launched in the U.S. in January 2025, with the UK's MHRA and the European... Read more
Hold if already holding. Not a fresh buy at $1.38, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $8.75 vs price $1.38 — ratio 6.3×). Rejected, falling back to technical TP.; Market cap $367M below $400M minimum. Chart setup: Oversold RSI 25, near Bollinger lower, volume surge. Market cap $367M below $400M minimum. Not in investable universe. Score 5.8/10, moderate confidence.
Passes 5/8 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and earnings proximity 5d<=7d. Suitability: speculative.
Recent developments
updated Nov 4, 2026Recent Developments — Autolus Therapeutics plc
Latest news
- NEWS Autolus Therapeutics Announces Publication of ASH Annual Meeting Abstracts — fiscal.ai Nov 4, 2026
- NEWS Autolus Therapeutics To Present Clinical Update Abstracts At American Society of Hematology Meeting, December 12-15 — benzinga Nov 4, 2026
- NEWS Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — fiscal.ai Nov 4, 2026
- NEWS HC Wainwright & Co. Assumes Coverage of Autolus Therapeutics with Buy Rating — fiscal.ai Nov 2, 2026
- NEWS HC Wainwright & Co. Assumes Autolus Therapeutics at Buy, Announces Price Target of $10 — benzinga Nov 2, 2026
Latest item Nov 4, 2026 · Generated 2026-11-05T11:44:07Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·2 ceiling hits
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Volatile — 7.1% daily ATR makes tight stops impractical. Position-size conservatively.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $1.38, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $8.75 vs price $1.38 — ratio 6.3×). Rejected, falling back to technical TP.; Market cap $367M below $400M minimum. Chart setup: Oversold RSI 25, near Bollinger lower, volume surge. Market cap $367M below $400M minimum. Not in investable universe. Resistance target $1.78 (+29.0%), stop $1.29 (−7.0%), A.R:R 0.0:1. Score 5.8/10, moderate confidence.
Resistance target: $1.78 (+29.0% upside). Resistance target $1.78 (+29.0%), stop $1.29 (−7.0%), A.R:R 0.0:1. Stop-loss: $1.29.
DATA_ISSUE: analyst_target_implausible (raw $8.75 vs price $1.38 — ratio 6.3×). Rejected, falling back to technical TP.; Market cap $367M below $400M minimum.
Autolus Therapeutics plc trades at a P/E of N/A (forward -2.2). TrendMatrix value score: 8.2/10. Verdict: Hold.
16 analysts rate AUTL, with a consensus score of 4.3/5. 8 analysts publish price targets averaging $9.
What does Autolus Therapeutics plc do?Autolus Therapeutics markets AUCATZYL (obe-cel), a CD19-targeted CAR T cell therapy for adult relapsed or refractory...
Autolus Therapeutics markets AUCATZYL (obe-cel), a CD19-targeted CAR T cell therapy for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia, approved by the FDA in November 2024 and launched in the U.S. in January 2025, with the UK's MHRA and the European Commission granting conditional and full marketing authorizations since. The company posted a $287.5 million net loss in 2025 against a $1,386.8 million accumulated deficit, and expects AUCATZYL to generate substantially all of its product revenue for the foreseeable future.